Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus type 4 and type 7 vaccine, live, oral (Duramed Research)
- Development stage
- Approved
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
DR-5001 is a live, oral vaccine developed by Duramed Research (a subsidiary of Barr Pharmaceuticals, now part of Teva) for the prevention of febrile acute respiratory disease (ARD) caused by adenovirus serotypes 4 and 7. It is specifically indicated for use in United States military recruits aged 17 through 50 years, a population historically at high risk for adenovirus outbreaks. The vaccine consists of two enteric-coated tablets, one containing live adenovirus type 4 and the other containing live adenovirus type 7. These viruses are not attenuated but are delivered to the intestine where they produce an asymptomatic infection that induces protective immunity. This vaccine replaced the previous version produced by Wyeth, which was discontinued in 1999, leading to a significant resurgence of ARD in military training centers until the new vaccine's approval in 2011.
- Other names
- Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
02
Targets
Adenovirus serotype 4 virion surface antigensHAdV-7 (Human adenovirus serotype 7)
Beyond the preview
Go deeper on adenovirus type 4 and type 7 vaccine, live, oral (Duramed Research).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus type 4 and type 7 vaccine, live, oral (Duramed Research).